Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

  • STATUS
    Recruiting
  • End date
    Oct 27, 2023
  • participants needed
    100
  • sponsor
    Gilead Sciences
Updated on 14 February 2021
Investigator
Gilead Study Team
Primary Contact
Ruane Clinical Research Group Inc (2.0 mi away) Contact
+75 other location

Summary

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR).

Details
Condition HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection
Treatment Optimized Background Regimen (OBR), Placebo Oral Tablet, Oral GS-6207, Subcutaneous GS-6207, Failing ARV Regimen, Oral Lenacapavir, Subcutaneous Lenacapavir
Clinical Study IdentifierNCT04150068
SponsorGilead Sciences
Last Modified on14 February 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note